Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jan 12, 2010


Zachary Zimmerman had been appointed as director of business development at Regulus Therapeutics, a Carlsbad, Calif.-based company that develops microRNA drugs.

Prior to joining Regulus, he spent five years in the business development group of Alnylam Pharmaceuticals. Before that, he was a senior research analyst for IDC's Life Sciences practice with a focus on disruptive technologies, and prior to that, a lead scientist at 454 Life Sciences.

Zimmerman holds a PhD in molecular, cellular, and developmental biology from the University of California, Santa Cruz.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.